Pain Self-Management and Patient-Oriented Dosing for Pain and in Retention Opioid Treatment

Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

1. Adults at least 18 years old from participating clinics

2. Ability to speak, read, and understand English

3. Capable of providing informed consent

4. Access to phone and/or internet

5. Documented diagnosis of Opioid Use Disorder (OUD)

6. Within <180 days (6 months) of a new treatment episode, ideally within 90 days (3months)

• New treatment episode is defined as not having received prescribedbuprenorphine treatment in an outpatient setting for OUD in the prior 30 days (1 month)

7. On a stable dose of an oral or sublingual buprenorphine mono or combination product (<4 times per day, daily dosage <32 mg) for at least 7 days during incident newepisode of care

8. Have high impact chronic pain (Grade 3), based on the Graded Chronic PainScale-Revised (GCPS-R)

Exclusion Criteria:

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Under 18 years of age

2. Have cancer-related pain

3. Are currently in jail, prison, or overnight facility as required by court of law orhave pending legal action that could prevent participation in study activities

4. Currently prescribed 32mg of an oral or sublingual buprenorphine mono or combinationproduct

5. Currently prescribed an injectable formulation of buprenorphine

6. Pregnancy or intention to become pregnant within 4 months of enrollment

7. Currently prescribed naltrexone

8. History of hypersensitivity to buprenorphine that a clinician-determined causedserious rash/hives/pruritus, bronchospasm, angioneurotic edema, or anaphylacticshock

Individuals with common comorbidities, such as depression, anxiety, or alcohol, methamphetamine, and other substance use disorders will not be excluded.